Optimization of HPMC and carbopol concentrations in non-effervescent floating tablet through factorial design

被引:52
作者
Acharya, Sujata [1 ]
Patra, Sradhanjali [1 ]
Pani, Nihar Ranjan [2 ]
机构
[1] Utkal Univ, Dept Pharmaceut Sci, Bhubaneswar 751004, Odisha, India
[2] Gayatri Coll Pharm, Dept Pharmaceut, Sambalpur, Odisha, India
关键词
Optimization; Response surface methodology; Non-effervescent floating tablet; Glipizide; IN-VITRO; DRUG-DELIVERY; RELEASE; FORMULATION; GLIPIZIDE; NATEGLINIDE; DISSOLUTION; BEHAVIOR; POLYMER;
D O I
10.1016/j.carbpol.2013.11.060
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
This study was to optimize HPMC K4M and carbopol 934 concentration in the development of non-effervescent floating tablets (NEFTs) of glipizide as model drug using 3(2) factorial design. The time required for releasing drug of 50% and 80% and similarity factor were the target responses. HPMC K4M and carbopol 934 concentrations were the variables. The response surface methodology and optimized polynomial equations were used to select the optimal formulation with desired responses. The excipients used in tablets were compatible with glipizide as per the results of isothermal stress testing and DSC study. The drug release of entire NEFTs followed zero order kinetics and non-Fickian diffusion mechanism. Validation of the optimization technique demonstrated the reliability of the model. The optimized formulation containing 124.33 mg HPMC K4M and 25.76 mg carbopol 934 was prepared according to the software determined levels. The stability study of the optimized formulation proved the integrity of the developed formulation. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:360 / 368
页数:9
相关论文
共 39 条
  • [1] In situ gelling, bioadhesive nasal inserts for extended drug delivery: In vitro characterization of a new nasal dosage form
    Bertram, U
    Bodmeier, R
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 27 (01) : 62 - 71
  • [2] Extracellular alkaline protease from Bacillus licheniformis NCIM-2042: Improving enzyme activity assay and characterization
    Bhunia, Biswanath
    Dutta, Debjani
    Chaudhuri, Surabhi
    [J]. ENGINEERING IN LIFE SCIENCES, 2011, 11 (02): : 207 - 215
  • [3] Bolton S., 1990, PHARM STAT
  • [4] British Pharmacopoeia Commission, 2007, BRIT PHARMACOPOEIA
  • [5] Chowdary K P R, 2003, AAPS PharmSciTech, V4, pE39
  • [6] Chowdary K.P.R., 2003, IND J PHARM SCI, V65, P591
  • [7] The macromolecular polymers for the preparation of hydrodynamically balanced systems-methods of evaluation
    Dorozynski, P
    Jachowicz, R
    Kulinowski, P
    Kwiecinski, S
    Szybinski, K
    Skórka, T
    Jasinski, A
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2004, 30 (09) : 947 - 957
  • [8] Glipizide - A review of the pharmacoeconomic implications of the extended-release formulation in Type 2 diabetes mellitus
    Foster, RH
    Plosker, GL
    [J]. PHARMACOECONOMICS, 2000, 18 (03) : 289 - 306
  • [9] Franz R. M., 1988, PHARM DOSAGE FORMS D, V1
  • [10] Development and in vitro evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride
    Gambhire, Manoj N.
    Ambade, Kshitij W.
    Kurmi, Sushma D.
    Kadam, Vilasrao J.
    Jadhav, Kisan R.
    [J]. AAPS PHARMSCITECH, 2007, 8 (03)